A case of autoimmune progesterone dermatitis in an adolescent female
- PMID: 16624703
- DOI: 10.1016/j.jpag.2006.01.050
A case of autoimmune progesterone dermatitis in an adolescent female
Abstract
Background: Progesterone-induced dermatitis is a rare disorder. It typically occurs in females due to an autoimmune phenomenon to endogenous progesterone production, but can also be caused by exogenous intake of a synthetic progestin. Here, we present a case of autoimmune progesterone dermatitis (AIPD) seen in an adolescent female.
Case: The patient is a 15-year-old Caucasian female with no significant past medical history and no prior exogenous hormone use, who presented to her primary care physician complaining of cyclic skin eruptions. She noted that her dermatologic symptoms occurred monthly, just prior to her menses. An intradermal skin test using 0.1 cc of progesterone was performed. The patient immediately developed a wheal, confirming the diagnosis of AIPD. The patient was begun on a continuous regimen of an oral contraceptive pill with 30 micrograms of ethinyl estradiol and 0.15 mg of levonorgestrel. The skin eruptions have not returned since the initiation of this therapy.
Conclusion: Autoimmune progesterone dermatitis manifests via the occurrence of cyclic skin eruptions. Women with the disorder commonly present with dermatologic lesions in the luteal phase of the menstrual cycle. Diagnosis of AIPD is confirmed by performing a skin allergen test using progesterone. Due to its rarity, AIPD should be considered a diagnosis of exclusion. In cases believed to be due to an endogenous production of progesterone, several methods of therapy have been attempted. The ultimate goal of therapy is the suppression of ovulation, which will prevent endogenous hormone production as progesterone is only produced in ovulatory cycles. Currently, the first-line choice of therapy is a combination oral contraceptive. If this treatment is ineffective, patients have been treated with danazol, gonadotropin releasing hormone analogs, tamoxifen, and oophorectomy with varying success.
Similar articles
-
Autoimmune progesterone anaphylaxis.Iran J Allergy Asthma Immunol. 2007 Jun;6(2):97-9. Iran J Allergy Asthma Immunol. 2007. PMID: 17563411
-
Autoimmune progesterone dermatitis.Gynecol Endocrinol. 2006 Jan;22(1):54-6. doi: 10.1080/09513590500216735. Gynecol Endocrinol. 2006. PMID: 16522535
-
Autoimmune Progesterone Dermatitis Diagnosed by Lymphocyte Transformation Test and Progesterone Provocation Test.Acta Dermatovenerol Croat. 2018 Oct;26(3):276-277. Acta Dermatovenerol Croat. 2018. PMID: 30390735
-
Autoimmune progesterone dermatitis and its manifestation as anaphylaxis: a case report and literature review.Ann Allergy Asthma Immunol. 2003 May;90(5):469-77; quiz 477, 571. doi: 10.1016/S1081-1206(10)61838-8. Ann Allergy Asthma Immunol. 2003. PMID: 12775127 Review.
-
Autoimmune progesterone dermatitis.Eur J Dermatol. 2002 Nov-Dec;12(6):589-91. Eur J Dermatol. 2002. PMID: 12459536 Review.
Cited by
-
Catamenial dermatoses associated with autoimmune, inflammatory, and systemic diseases: A systematic review,.Int J Womens Dermatol. 2019 Oct 25;5(5):361-367. doi: 10.1016/j.ijwd.2019.09.008. eCollection 2019 Dec. Int J Womens Dermatol. 2019. PMID: 31909158 Free PMC article. Review.
-
Autoimmune Progesterone Dermatitis.Indian J Dermatol. 2018 Mar-Apr;63(2):188-190. doi: 10.4103/ijd.IJD_166_17. Indian J Dermatol. 2018. PMID: 29692467 Free PMC article. No abstract available.
-
Progesterone hypersensitivity: a cyclical history.BMJ Case Rep. 2023 Nov 23;16(11):e256353. doi: 10.1136/bcr-2023-256353. BMJ Case Rep. 2023. PMID: 37996147
-
Recurrent bullous erythema multiforme due to oral contraceptive therapy.Int J Womens Dermatol. 2024 Apr 2;10(2):e142. doi: 10.1097/JW9.0000000000000142. eCollection 2024 Jun. Int J Womens Dermatol. 2024. PMID: 38572265 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous